Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics & Global Health World Congress 2016

Hariharan Subramanian's Biography



Hariharan Subramanian, Research Assistant Professor; Chief Technology Officer, NanoCytomics, Northwestern University

Dr. Subramanian is a biomedical engineer whose work focuses on translating academic research into commercially successful technologies. He is currently Research Assistant Professor at Northwestern University and Chief Technology Officer at NanoCytomics, and has over 10 years of experience in tissue optics, light scattering and spectroscopic microscopy. He was one of the original developers of the technology behind Partial Wave Spectroscopic Microscopy. He is currently spearheading the clinical implementation of the technology for application in screening different cancers including Lung, Colon, Pancreatic, Prostate, Esophageal, and Ovarian cancer as well as developing the application of PWS microscopy to understand biological processes in live cells. He has also developed optical sensors that can detect blood flow and oxygenation in real time as well as novel signal processing algorithms that can measure blood content in real time. Dr. Subramanian has considerable experience in the area of biomedical optics with publications in leading journals such as PNAS, Physical Review Letters, Optics Letters, and Physical Review E. He also has extensive experience in clinical research with publications in journals such as Cancer Research and Biophysical Journal.

Hariharan Subramanian Image

Nanocytology: Personalizing Cancer Risk Assessment in Primary-Care Setting

Tuesday, 27 September 2016 at 14:30

Add to Calendar ▼2016-09-27 14:30:002016-09-27 15:30:00Europe/LondonNanocytology: Personalizing Cancer Risk Assessment in Primary-Care SettingPoint-of-Care Diagnostics and Global Health World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Alterations in higher order chromatin structure are some of the earliest events in carcinogenesis and a marker of field carcinogenesis. These nanoscale markers can be detected by an emerging technology, nanocytology. Clinical studies have shown that the analysis of chromatin nanoarchitecture of cells obtained from easily accessible surrogate tissue sites via nanocytology has a remarkable accuracy for early cancer. This may allow increasing the detection rate of significant pre-neoplastic or neoplastic lesions while reducing overdiagnosis. Data from multi-institutional clinical trials has demonstrated that nanocytology has the potential to become a new platform for cancer screening broadly applicable to a number of neoplasms including lung cancer screening via buccal nanocytology, colon cancer screening via rectal nanocytology, and ovarian cancer screening via endocervical nanocytology.


Add to Calendar ▼2016-09-26 00:00:002016-09-28 00:00:00Europe/LondonPoint-of-Care Diagnostics and Global Health World Congress 2016Point-of-Care Diagnostics and Global Health World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com